About Molecure S.A.

Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.

Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access untapped, novel biology targets.

We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science and technology.

Our most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023.

Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase I clinical development in the second half of 2022.

Molecure’s headquarters and laboratories are located in Warsaw, with an additional laboratory facility in Łódź, Poland. The company is listed on the Warsaw Stock Exchange (ticker: MOC).

About Molecure S.A.

Our Leadership

Our team brings together exceptional capabilities in medicinal chemistry and translational science combined with an experienced entrepreneurial management team that are passionate about exploring the unexplored.

Management Board

Marcin Jan Szumowski

PRESIDENT OF THE BOARD,
CHIEF EXECUTIVE OFFICER

Sławomir Piotr Broniarek

MEMBER OF THE BOARD,
CHIEF FINANCIAL OFFICER

Adam Gołębiowski

MEMBER OF THE BOARD,
VP RESEARCH CHEMISTRY

Zbigniew Zasłona

MEMBER OF THE BOARD,
VP RESEARCH BIOLOGY

Agnieszka Rajczuk-Szczepańska

MEMBER OF THE BOARD,
HR DIRECTOR

Supervisory Board

Piotr Żółkiewicz

CHAIRMAN OF THE SUPERVISORY BOARD

Tomasz Piec

VICE-CHAIRMAN OF THE SUPERVISORY BOARD

Mariusz Gromek

MEMBER OF THE SUPERVISORY BOARD

Nancy Van Osselaer, PhD

MEMBER OF THE SUPERVISORY BOARD

Paul Van der Horst, PhD

MEMBER OF THE SUPERVISORY BOARD

Paweł Trawkowski

MEMBER OF THE SUPERVISORY BOARD

Management Team

Jacek Olczak

HEAD OF MEDICINAL CHEMISTRY

Samson Fung

CHIEF MEDICAL OFFICER

Magdalena Tyszkiewicz

HEAD OF CMC

Anna Bajera

DIRECTOR OF CLINICAL OPERATIONS

Marta Dudek

MEDICAL DIRECTOR

Nicolas Beuzen

DIRECTOR OF BUSINESS DEVELOPMENT AND LICENSING

Marta Borkowska

DIRECTOR OF THE MANAGEMENT BOARD OFFICE

Scientific Advisory Board

Bart Lambrecht

MD, PhD

Nancy Van Osselaer

PhD

Reynold A. Panettieri Jr.

MD, PhD

Douglas Hay

PhD

Bruce Conway

PhD

Rafał Krenke

MD, PhD

This site is registered on wpml.org as a development site.